Dupilumab in Chinese Adult Participants With CRSwNP
Status:
Recruiting
Trial end date:
2024-12-25
Target enrollment:
Participant gender:
Summary
This is a parallel group, Phase 3, 2-arm study for treatment. The purpose of this study is to
evaluate dupilumab subcutaneous (SC) injections compared to placebo in Chinese adult
participants with CRSwNP, on a background therapy with intranasal corticosteroids (budesonide
nasal spray).
Study details include:
- The study duration will be up to 40 weeks.
- The treatment duration will be up to 24 weeks.
- The number of visits will be 7.